Drug Trial Radar · NCT07001995
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Last checked: Nov 19, 2026Latest source record: Mar 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
May 1, 2026
Primary completion
Dec 30, 2027
Study completion Dec 30, 2028
Sponsor
- Lead sponsor
- Hunan Province Tumor HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single-center, prospective study and aims to evaluate the efficacy and safety of limertinib combined with etoposide and carboplatin in EGFR-mutant NSCLC patients who develop small-cell lung cancer transformation following progression on EGFR-TKI therapy.
Conditions
- Small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer NSCLC
Interventions
limertinibDrug
limertinib 80 mg
etoposide and carboplatinDrug
etoposide 100 mg/m² IV D1-3 + carboplatin AUC 5-6 IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Time from first subject dose to study completion, or up to 36 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yongchang Zhang
Changsha, Hunan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.